To date, the utility of immunohistochemistry (IHC) markers has not been established in DCIS diagnostics, in contrast to IBC, where the hormone receptors (HRs) for estrogen (ER) and progesterone (PR), HER2, and Ki67 proliferation index are all deciding on a complex treatment algorithm. The gene discussed is ESR1; the disease is inflammatory breast carcinoma.